LandmarkObservational

TROIA / PROMETHEUS

Ultra-Slow Infusion of Low-Dose Recombinant Tissue Plasminogen Activator for Obstructive Prosthetic Valve Thrombosis

J Am Coll Cardiol, 2013 · Prospective cohort study of consecutive protocolized fibrinolytic regimens

Clinical question

Does an ultra-slow low-dose tPA infusion achieve successful lysis with minimal hemorrhage in obstructive prosthetic valve thrombosis?

Population: 182 episodes of obstructive prosthetic heart valve thrombosis
Intervention: Low-dose (25 mg), ultra-slow (25-hour) intravenous infusion of tPA without bolus
Comparator: Accelerated and conventional high-dose fibrinolytic regimens
Primary outcome: Thrombus resolution, mortality, and major bleeding complications
Result: The ultra-slow 25-hour low-dose tPA regimen achieved a 90% success rate with 0.5% mortality and 1.6% major bleeding, compared to ~15–20% complications with accelerated regimens. (90% success, 1.6% major bleeding, <0.001)

What the trial found

Slow infusion of low-dose tPA (25 mg over 25 hours) without a bolus effectively dissolves obstructive mechanical valve thrombi with exceptionally low major bleeding and embolic risk.

Current guideline position

Supported in 2020 ACC/AHA and 2021 ESC/EACTS valvular heart disease guidelines as a safe alternative to urgent reoperation.

Clinical interpretation

Establishes slow-infusion low-dose fibrinolysis as the preferred first-line medical rescue regimen for critically ill patients with obstructive prosthetic valve thrombosis who are poor surgical candidates or have right-sided valve thrombosis.

Moderate certainty

Clinical Context & Relevant Topics (3)

Disease Reference

Valvular Heart Disease & Infective Endocarditis in the ICU

Critical AS, acute AR/MR mechanics, prosthetic valve emergencies, and infective endocarditis with multidisciplinary surgical triggers.

View Topic Context →

Cardiogenic Shock

Primary pump failure, SCAI staging (A–E), PAC hemodynamics (CPO, PAPi), inotrope selection, emergent revascularization, and mechanical circulatory support.

View Topic Context →

Major Bleeding, Hemorrhagic Shock, & Damage Control Resuscitation

The trauma lethal diamond (hypothermia, acidosis, coagulopathy, hypocalcemia), 1:1:1 massive transfusion (PROPPR trial), early TXA (CRASH-2), and TEG/ROTEM algorithms.

View Topic Context →